<DOC>
	<DOCNO>NCT01403922</DOCNO>
	<brief_summary>This two part study . Part 1 determine determine administration TC-5214 effect sit blood pressure patient chronic hypertension . Part 2 determine possible interaction TC-5214 Anti-Hypertensive Medications ( Calcium Channel Blockers , Beta Blockers , ACE Inhibitors ) .</brief_summary>
	<brief_title>To Determine Blood Pressure Interaction Between TC-5214 Anti-Hypertensive Medications ( Calcium Channel Blockers , Beta Blockers , ACE Inhibitors ) Patients With Chronic Hypertension</brief_title>
	<detailed_description>A Phase I Randomised , Placebo-Controlled , Double-Blind Study Hypertensive Patients Blood Pressure Interaction TC-5214 Anti-Hypertensive Medications ( Calcium Channel Blockers , Beta Blockers , ACE Inhibitors )</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Male female patient chronic , stable hypertension treat least 1 month screen calcium channel blocker , beta blocker , ACE inhibitor , either antihypertensive medication concurrently diuretic . The patient change current anti hypertensive treatment least 1 month dose Patients Part 1 SBP ≤140 mmHg screen ≤160 mmHg Visit 1a predose Day 1 Patients Part 2 SBP ≤160 mmHg screen Visit 1 pre dose Day 1 . Systolic blood pressure DBP vary 8 mmHg 5 mmHg , respectively , predose period ( screen , Visit 1a , predose Day 1 ) Age 18 65 year ( inclusive ) Other chronic hypertension , history clinically significant medical , neurologic , psychiatric disease disorder , opinion Investigator and/or Sponsor , may either put patient risk participation study influence result , patient 's ability participate study . Patients dyslipidaemia ( diet control treated statin ) and/or metabolic syndrome ( diet control treated metformin ) may enter study Any clinically significant illness , medical/surgical procedure trauma within 4 week first administration investigational product Patients pretreatment SBP ( know ) &gt; 180 mmHg history accelerate malignant hypertension base grade III ( hypertensive haemorrhage and/or cotton wool spot ) grade IV ( hypertensive papilloedema ) retinopathy time History presence gastrointestinal ( include irritable bowel disease ) , hepatic , renal disease ( creatinine clearance ≤50 mL/minute calculate use Cockcroft Gault equation ) condition know interfere ADME investigational product . Patients history surgery gastrointestinal tract ( include appendectomy cholecystectomy ) also exclude Any significant ECG abnormality include QTcF prolongation ( &gt; 450 m ) significant arrhythmia , junctional rhythm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Phase I , Randomised , Placebo-Controlled , Double-Blind , Hypertensive Patients , Blood Pressure , Calcium Channel Blockers , Beta Blockers , ACE Inhibitors</keyword>
	<keyword>Scientific terminology : To determine treatment TC5214 alone combination Anti-Hypertensive Medications effect sit blood pressure</keyword>
	<keyword>Laymen terminology : Hypertension</keyword>
</DOC>